Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amsterdam, Netherlands Clinical Trials

A listing of Amsterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (39) clinical trials

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

This is a Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects with Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with EGFRvIII-positive glioblastoma. This study will enroll 2 groups ...

Phase

2.84 miles

Learn More »

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

Phase

2.84 miles

Learn More »

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

This multicentre, open-label, dose escalating, Phase I study will enrol approximately 18 patients with progressive and/or multiple recurrent GBM, who after failure of standard therapies will receive GMP Human- recombinant Bone Morphogenetic Protein 4 via intra-tumour and interstitial delivery by CED. Patients will undergo a resection or biopsy of the ...

Phase

2.84 miles

Learn More »

Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma

The study will be conducted in 2 parts, separately for intravenous (IV) and subcutaneous (SC) administration: dose escalation and dose expansion. The study will evaluate safety, tolerability, pharmacokinetics and preliminary antitumor activity of JNJ-64407564 administered to adult participants with relapsed or refractory multiple myeloma. The overall safety of the study ...

Phase

2.84 miles

Learn More »

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

This first-in-human trial with ABL001 is a dose escalation study whose primary purpose is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of single agent ABL001 in CML or Ph+ ALL patients, and in combination with either Nilotinib or Imatinib or Dasatinib in Ph positive ...

Phase

2.84 miles

Learn More »

Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)

Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months). The median overall survival for GBM patients is 12-14 months from the time of diagnosis; therefore the development ...

Phase

2.84 miles

Learn More »

PET Study With [89Zr]-Df-CriPec Docetaxel

In order to improve tumour targeting drug molecules can be transformed into biodegradable nanoparticle compounds thereby creating nanomedicines designed to improve the therapeutic profile of drugs. Based on this technology, the nanoparticle CriPec docetaxel (developed by Cristal Therapeutics) contains docetaxel conjugated to a linker agent. This docetaxel-linker conjugate is thereafter ...

Phase

2.84 miles

Learn More »

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

The main objective of this study is to determine the biodistribution and intra-tumor accumulation of [89Zr]Zr-BI 754111 at baseline and its change upon treatment

Phase

2.84 miles

Learn More »

Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects

The purpose of this study is the evaluation of the safety of autologous tissue-engineered dermal substitutes "denovoDerm" (first arm) and dermo-epidermal skin substitutes "denovoSkin" (second arm) transplanted onto the wound bed in children and adults.

Phase

3.1 miles

Learn More »

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

This study has been designed as a Phase I, open-label, dose finding study with a dose escalation part and a dose expansion part in adult patients with selected advanced solid tumors. The study treatment, TNO155, will be taken until the patient experiences unacceptable toxicity, progressive disease and/or treatment is discontinued ...

Phase

3.5 miles

Learn More »